Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin

Aim:  To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome.

[1]  F. E. Yakubu-Madus,et al.  Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. , 1999, Diabetes.

[2]  J. Montani,et al.  Pathways from obesity to hypertension: from the perspective of a vicious triangle , 2002, International Journal of Obesity.

[3]  P. Ernsberger,et al.  Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). , 1999, The Journal of pharmacology and experimental therapeutics.

[4]  F. Messerli,et al.  Moxonidine: a new and versatile antihypertensive. , 2000, Journal of cardiovascular pharmacology.

[5]  C. Bailey.  Biguanides and NIDDM , 1992, Diabetes Care.

[6]  T. Wilkin,et al.  Metabolic syndrome: maladaptation to a modern world. , 2004, Journal of the Royal Society of Medicine.

[7]  M. Schachter,et al.  Metabolic effects of moxonidine and other centrally acting antihypertensives , 1999, Diabetes, obesity & metabolism.

[8]  A. Wierzbicki,et al.  Effect of moxonidine on lipid subfractions in patients with hypertension , 2004, International journal of clinical practice.

[9]  P. Ernsberger,et al.  Contribution of sympathetic nervous system overactivity to cardiovascular and metabolic disease , 1998 .

[10]  P. Ernsberger,et al.  Sympathetic nervous system in salt-sensitive and obese hypertension: Amelioration of multiple abnormalities by a central sympatholytic agent , 1996, Cardiovascular Drugs and Therapy.

[11]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[12]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[13]  H. Lithell.  Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism , 1991, Diabetes Care.

[14]  Metabolic effects of metformin in patients with impaired glucose tolerance , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[15]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[16]  A. Scheen,et al.  Management of the metabolic syndrome. , 2004, Minerva endocrinologica.

[17]  S. Haffner,et al.  Metabolic syndrome – a new risk factor of coronary heart disease? , 2003, Diabetes, obesity & metabolism.

[18]  H. Lithell,et al.  Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. , 1999, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[19]  R. Krauss.  Lipids and lipoproteins in patients with type 2 diabetes. , 2004, Diabetes care.

[20]  S. Jacob,et al.  Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats. , 1997, Hypertension.

[21]  M. Matsuda,et al.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. , 1999, Diabetes care.

[22]  U. Smith,et al.  Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors , 1991, Journal of internal medicine.

[23]  J. Jaspan,et al.  Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes , 1987, Diabetes.

[24]  T. Kotchen,et al.  Epidemiologic, physiologic, and clinical implications of hypertension and insulin resistance , 1993 .

[25]  P. J. Berry.  United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years , 1995, BMJ.

[26]  J. Yudkin,et al.  Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groups , 1993, Diabetes Care.

[27]  V. A. Almazov,et al.  INSULIN RESISTANCE AND ARTERIAL HYPERTENSION. THE INFLUENCE OF MOXONIDINE AND METFORMIN THERAPY: 2B.6 , 2000 .

[28]  R. Marfella,et al.  Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women , 1993, Diabetes Care.

[29]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .